Potential of Genetically- Modified Measles Virus as A Treatment Modality For Carcinoma: A Review
Open Access
- 25 June 2018
- journal article
- review article
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 11 (2), 917-922
- https://doi.org/10.13005/bpj/1448
Abstract
Malignancy is a disease in which cell division is uncontrolled and prognosis is often poor. Despite recent advances in the felid of medicine the life expectancy after the diagnosis of advanced stages of cancers has high mortality rates . The traditional methods of treatment have low curative effects and high risk of side effects. Further the possibility of re-occurrence is not completely eliminated by any of the conventional methods of treatment. Thus, a technique that affects only the tumour cells without leaving behind any cancer initiator cells must be deviced. Recently genetically modified variants of measles virus were used to cure multiple myeloma .The idea to use of measles virus dates back to 1950’s.Constant research has lead the advent of a branch known as oncolytic virotheraphy . Precise targeting of cancer cells is one of the dominant advantages of cancer therapy through virus and it can be achieved in multiple manners. A few viruses such as exclusively replicating mumps virus, moloney leukemia virus, parvoviruses, reovirus, newcastle disease virus have a natural preference for malignant cells, whereas vesicular stomatitis adenovirus, virus, measles, vaccinia and herpes simplex virus can be adapted or engineered to make them cancer-specific.Keywords
This publication has 23 references indexed in Scilit:
- Therapeutic Potential of Oncolytic Measles Virus: Promises and ChallengesClinical Pharmacology & Therapeutics, 2010
- Targeting Cancer-initiating Cells With Oncolytic VirusesMolecular Therapy, 2009
- Reprogrammed viruses as cancer therapeutics: targeted, armed and shieldedNature Reviews Microbiology, 2008
- Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of ReovirusClinical Cancer Research, 2008
- History of Oncolytic Viruses: Genesis to Genetic EngineeringMolecular Therapy, 2007
- Cyclophosphamide Increases Transgene Expression Mediated by an Oncolytic Adenovirus in Glioma-Bearing Mice Monitored by Bioluminescence ImagingMolecular Therapy, 2006
- Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responsesProceedings of the National Academy of Sciences of the United States of America, 2006
- Measles: not just another viral exanthemThe Lancet, 2003
- SLAM (CDw150) is a cellular receptor for measles virusNature, 2000
- Cultivation of Poliomyelitis Virus in Cultures of Human Foreskin and Embryonic Tissues.Experimental Biology and Medicine, 1949